Previous 10 | Next 10 |
Halvorsen's 13F portfolio value decreased from $36.04B to $34.49B this quarter. The number of positions increased from 96 to 107. Viking Global added Twilio, Workday, and Aon plc while dropping Fidelity National Information Services and Snowflake. The top three positions are Ginkg...
SMBC Nikko has initiated Inhibrx (INBX +10.7%) with an outperform rating given the company's focus on therapeutic antibodies targeting agonist immuno-oncology targets. The first has a $40 price target (~98% upside based on Tuesday's close) Analyst David Dai cited Inhibrx (INBX +10.7%) candida...
The U.S. Food and Drug Administration granted orphan drug designation to Inhibrx's (INBX) INBRX-101 to treat alpha-1 antitrypsin deficiency, or AATD. AATD is an inherited disease characterized by deficient levels of the AAT protein, which causes loss of lung tissue and function and decre...
Inhibrx Receives FDA Orphan-Drug Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency - Interim results reported in October 2021 from the Phase 1 study showed a favorable safety and tolerability profile with no drug-related severe or serious adverse even...
Inhibrx press release (NASDAQ:INBX): Q4 GAAP EPS of -$0.55 beats by $0.02. Revenue of $2.86M (+2.9% Y/Y) beats by $1.15M. For further details see: Inhibrx GAAP EPS of -$0.55 beats by $0.02, revenue of $2.86M beats by $1.15M
Inhibrx Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Recent Corporate Highlights PR Newswire SAN DIEGO , Feb, 28, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong e...
Inhibrx Announces Amended Loan Agreement with Oxford PR Newswire SAN DIEGO , Feb. 22, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today announced that i...
Inhibrx Announces Initial Phase 1 Dose Escalation Results for INBRX-106, a Novel Hexavalent OX40 Agonist, in Combination with Keytruda® (Pembrolizumab) Along with Updated Single Agent Data - Two durable partial responses in checkpoint inhibitor-naive nasopharyngeal carcinom...
The FDA has given Orphan Drug designation to Inhibrx's (NASDAQ:INBX) INBRX-109 for chondrosarcoma. The condition is a bone cancer with ~2,800 patients diagnosed annually in the United States and the European Union. In January, INBRX-109 received Fast Track designation for unres...
Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma - Orphan-drug designation follows fast track designation granted to INBRX-109 in conventional chondrosarcoma - Preliminary median progression-free survival (PFS) of 7.4 months and disease control ra...
News, Short Squeeze, Breakout and More Instantly...
Inhibrx Inc. Company Name:
INBX Stock Symbol:
NASDAQ Market:
2024-07-23 06:30:08 ET JMP Securities analyst issues MARKET PERFORM recommendation for INBX on July 23, 2024 04:40AM ET. The previous analyst recommendation was Outperform. INBX was trading at $13.49 at issue of the analyst recommendation. The overall analyst consensus :...
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...
Smart Share Global Limited (EM) is expected to report for Q1 2024 American Rebel Holdings Inc. (AREB) is expected to report for Q1 2024 First Republic Bank (San Francisco, California) (FRCB) is expected to report for Q1 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ...